• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICROVENTION, INC FRED X21; INTRALUMINAL DEVICES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICROVENTION, INC FRED X21; INTRALUMINAL DEVICES Back to Search Results
Model Number FREDX2518-PMA
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Thrombosis/Thrombus (4440)
Date of Event 03/22/2023
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
A visual inspection of the device captured in this file could not be performed as a physical device was not returned for evaluation.No product(s) were returned for evaluation, however one image was provided by the customer for evaluation.An image review found upmc occluded fredx 21 stent: lateral ica dsa (not labeled as to time or side), subtracted, with contrast, centered only on petrous, cavernous and supraclinoid ica.The visualized ica is normal.The ghost of coils in the coiled pcom aneurysm is seen.The horizontal portion of the distal fred is vaguely seen as a movement artifact.This single image is insufficient to pass any comment(s) on the complication described.Without the return and physical evaluation of the device, the investigation cannot definitively determine if a condition existed that would have caused or contributed to the reported event.Based on a review of the device¿s risk documentation, the reported event did not indicate there were any potential or new manufacturing, design, quality, or other systemic issues, or non-conformances.The complaint code is monitored through the trending process; corrective action is determined, as needed, through this process.Investigations of historic complaint files with similar complaint category coding are recorded in the complaint handling system; without the ability to perform and analysis of the device, this investigation cannot identify with certainty any potential root causes.A search for non-conformances associated with this part/lot number combination did not reveal any production-related issues relevant to the complaint that occurred during manufacturing of the device.There are no similar complaints based on the complaint category regarding this batch number from the last two years recorded in the complaint system at the time of this investigation.Ifu review (additional information can be found in the ifu).Potential complications.Below is a list of the probable adverse effects (e.G., complications) associated with the use of neurovascular flow diverting stents: ¿ allergic reaction, including but not limited to: contrast dye, nitinol metal, and any other medications used during the procedure; ¿ amaurosis fugax or transient blindness; ¿ aphasia; ¿ blindness; ¿ cardiac arrhythmia; ¿ complications of arterial puncture including pain, local bleeding, or injury to the artery, or adjacent nerves; ¿ cranial neuropathy; ¿ death; ¿ device fracture, migration or misplacement; ¿ diplopia; ¿ dissection or perforation of the parent artery; ¿ headache; ¿ hemiplegia; ¿ hemorrhage, including intracranial hemorrhage (ich), subarachnoid hemorrhage (sah), and retroperitoneal; ¿ hydrocephalus; ¿ infection; ¿ mass effect; ¿ myocardial infarction; ¿ neurological deficits; ¿ pseudoaneurysm formation; ¿ reactions to anti-platelet or anti-coagulant agents; ¿ reactions due to radiation exposure, including alopecia, burns ranging in severity from skin reddening to ulcers, cataracts, and delayed neoplasia.¿ reactions to anesthesia and related procedures; ¿ reactions to contrast agents including allergic reactions and kidney failure; ¿ reduced visual acuity or visual field; ¿ retinal artery occlusion or infarction; ¿ retinal ischemia; ¿ rupture or perforation of the aneurysm; ¿ stenosis of stented segment; ¿ seizure; ¿ stent thrombosis; ¿ stroke or tia (transient ischemic attack); ¿ thromboembolic event; ¿ vasospasm; ¿ visual impairment.I.Directions for use.26.Note: a slow, proper push/pull technique, encompassing sufficient delivery wire push force, in addition to an opposing microcatheter withdrawal force, to remove excess microcatheter slack while maintaining the microcatheter tip within the center of the parent vessel, will facilitate properly deploying the fred system at the proper location, to achieve full expansion and good vessel apposition.27.Caution: using a rapid microcatheter withdrawal technique to deploy the fred system is not recommended and may result in device elongation or improper deployment.Be aware of delivery wire tip position during deployment.28.If the fred system positioning is not satisfactory, the implant may be recaptured and repositioned if it is not fully deployed.The implant may be recaptured up to 75% of its deployed length.29.Caution: if resistance is felt while recapturing the device, do not continue to recapture.Withdraw the microcatheter slightly to unsheath the device (without exceeding the recapture limit), and then attempt to recapture again.30.Caution: the fred system must not be re-deployed more than three times.31.If fred system positioning is satisfactory, carefully advance the delivery wire while retracting the microcatheter as needed to minimize slack, maintaining the microcatheter around the center of the parent vessel, to allow the implant to deploy across the neck of the aneurysm.Ensure the implant proximal radiopaque end markers are in the advised position (see step 23) proximal to the aneurysm neck for adequate coverage.32.Note: the fred system will expand and may foreshorten up to 60% from its undeployed length.Visually verify opening of the proximal end, ensuring that the microcatheter distal tip marker is pulled back, adequately away from the implant proximal end, to allow the proximal end to freely open.Push forward on the delivery wire to assist in maintaining access within the implant as needed.33.Note: visualize and refer to implant radiopaque end markers to maintain adequate implant length on each side of the aneurysm neck/target location to ensure appropriate coverage.34.Warning: do not fully deploy the fred system if positioning in the parent vessel is not satisfactory.35.If necessary, to maintain access through the implanted device, advance the microcatheter distal to the implanted device.Remove and discard the delivery wire.36.Caution: the fred system delivery wire should not be utilized as a guidewire.Do not torque the fred system.A torque device should not be used.37.Carefully inspect the deployed fred implant under fluoroscopy to confirm that it is completely open and opposed to the vessel wall and not kinked.If the implant is not fully open and apposed or is kinked, consider utilizing a suitable micro guidewire and/or occlusion balloon catheter to fully open the implant.38.After completing the procedure, withdraw and discard all applicable accessory devices.Caution: carefully watch the fred implant distal and proximal markers when passing through the implanted device with other devices to avoid displacing the implant.H3 other text : device remains implanted.
 
Event or Problem Description
It was reported the physician placed the flow diverter from the rt pca to the right pcomm and coiled the aneurysm through the vert.It was noted that post procedure everything looked good.The physician did a follow up a week later and noticed thrombus in the stent and gave some thrombolytics.The medication cleared the thrombus up.The physician did the 6 month follow up and the stent was completely thrombosed.The pca was being filled by collaterals from the aca and mca.The patient was doing well, device remains implanted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
FRED X21
Common Device Name
INTRALUMINAL DEVICES
Manufacturer (Section D)
MICROVENTION, INC
35 enterprise
aliso viejo CA 92656
Manufacturer Contact
terrence callahan
35 enterprise
aliso viejo, CA 92656
7142478000
MDR Report Key16765645
Report Number2032493-2023-00673
Device Sequence Number20378909
Product Code OUT
UDI-Device Identifier00842429114223
UDI-Public(01)00842429114223(11)210401(17)240331(10)0000135917
Combination Product (Y/N)N
Initial Reporter StatePA
Initial Reporter CountryUS
PMA/510(K) Number
P180027
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 04/18/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date03/24/2024
Device Model NumberFREDX2518-PMA
Device Catalogue NumberFREDX2518
Device Lot Number0000135917
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 03/22/2023
Initial Report FDA Received Date04/18/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured04/01/2021
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient SexMale
-
-